Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation

The Hereditary Ovarian Cancer Clinical Study Group, Joanne Kotsopoulos, Jacek Gronwald, Beth Karlan, Barry Rosen, Tomasz Huzarski, Pal Moller, Henry T. Lynch, Christian F. Singer, Leigha Senter, Susan L. Neuhausen, Nadine Tung, Andrea Eisen, William D. Foulkes, Peter Ainsworth, Ping Sun, Jan Lubinski, Steven A. Narod

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Objectives: For women at high risk of developing ovarian cancer, it is important to provide an accurate recommendation for the optimal age for preventive surgery in order to maximize the preventative effect while delaying symptoms associated with early surgical menopause. The goal of the current study was to estimate age-specific incidence rates of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Methods: From our international registry, we identified 5689 women with no previous diagnosis of ovarian or fallopian tube cancer or preventive oophorectomy. Women were followed from the date of completion of the baseline questionnaire until either a diagnosis of ovarian or fallopian tube cancer, prophylactic oophorectomy, death or last follow-up. The annual and cumulative incidence rates of ovarian cancer were estimated. Results: Over a mean follow-up period of 4.7 years (ranges 0–22.6), 195 incident ovarian or fallopian tube cancers were diagnosed (169 [86%] ovarian cancers, 22 [11%] fallopian tube cancers and four [2%] cancers that involved both the ovaries and fallopian tubes). Of these, 45 (23%) cancers were diagnosed at preventive surgery (occult cancers). The cumulative risk of ovarian cancer to age 80 was 49% for BRCA1 and 21% for BRCA2 mutation carriers. The mean age at diagnosis was 51.3 years (ranges 33–84) among women with a BRCA1 mutation and 61.4 years (ranges 44–80) among women with a BRCA2 mutation. Conclusion: Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects.

LanguageEnglish (US)
Pages85-91
Number of pages7
JournalGynecologic Oncology
Volume150
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Ovarian Neoplasms
Fallopian Tube Neoplasms
Mutation
Ovariectomy
Neoplasms
Fallopian Tubes
Incidence
Menopause
Registries
Ovary

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. / The Hereditary Ovarian Cancer Clinical Study Group.

In: Gynecologic Oncology, Vol. 150, No. 1, 01.07.2018, p. 85-91.

Research output: Contribution to journalArticle

The Hereditary Ovarian Cancer Clinical Study Group. / Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. In: Gynecologic Oncology. 2018 ; Vol. 150, No. 1. pp. 85-91.
@article{5f4c0d2bd72b496a966b69fef0746bd7,
title = "Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation",
abstract = "Objectives: For women at high risk of developing ovarian cancer, it is important to provide an accurate recommendation for the optimal age for preventive surgery in order to maximize the preventative effect while delaying symptoms associated with early surgical menopause. The goal of the current study was to estimate age-specific incidence rates of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Methods: From our international registry, we identified 5689 women with no previous diagnosis of ovarian or fallopian tube cancer or preventive oophorectomy. Women were followed from the date of completion of the baseline questionnaire until either a diagnosis of ovarian or fallopian tube cancer, prophylactic oophorectomy, death or last follow-up. The annual and cumulative incidence rates of ovarian cancer were estimated. Results: Over a mean follow-up period of 4.7 years (ranges 0–22.6), 195 incident ovarian or fallopian tube cancers were diagnosed (169 [86{\%}] ovarian cancers, 22 [11{\%}] fallopian tube cancers and four [2{\%}] cancers that involved both the ovaries and fallopian tubes). Of these, 45 (23{\%}) cancers were diagnosed at preventive surgery (occult cancers). The cumulative risk of ovarian cancer to age 80 was 49{\%} for BRCA1 and 21{\%} for BRCA2 mutation carriers. The mean age at diagnosis was 51.3 years (ranges 33–84) among women with a BRCA1 mutation and 61.4 years (ranges 44–80) among women with a BRCA2 mutation. Conclusion: Based on a cumulative risk of 0.55{\%} to age 35 for BRCA1 mutation carriers and of 0.56{\%} to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects.",
author = "{The Hereditary Ovarian Cancer Clinical Study Group} and Joanne Kotsopoulos and Jacek Gronwald and Beth Karlan and Barry Rosen and Tomasz Huzarski and Pal Moller and Lynch, {Henry T.} and Singer, {Christian F.} and Leigha Senter and Neuhausen, {Susan L.} and Nadine Tung and Andrea Eisen and Foulkes, {William D.} and Peter Ainsworth and Ping Sun and Jan Lubinski and Narod, {Steven A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ygyno.2018.05.011",
language = "English (US)",
volume = "150",
pages = "85--91",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation

AU - The Hereditary Ovarian Cancer Clinical Study Group

AU - Kotsopoulos, Joanne

AU - Gronwald, Jacek

AU - Karlan, Beth

AU - Rosen, Barry

AU - Huzarski, Tomasz

AU - Moller, Pal

AU - Lynch, Henry T.

AU - Singer, Christian F.

AU - Senter, Leigha

AU - Neuhausen, Susan L.

AU - Tung, Nadine

AU - Eisen, Andrea

AU - Foulkes, William D.

AU - Ainsworth, Peter

AU - Sun, Ping

AU - Lubinski, Jan

AU - Narod, Steven A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objectives: For women at high risk of developing ovarian cancer, it is important to provide an accurate recommendation for the optimal age for preventive surgery in order to maximize the preventative effect while delaying symptoms associated with early surgical menopause. The goal of the current study was to estimate age-specific incidence rates of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Methods: From our international registry, we identified 5689 women with no previous diagnosis of ovarian or fallopian tube cancer or preventive oophorectomy. Women were followed from the date of completion of the baseline questionnaire until either a diagnosis of ovarian or fallopian tube cancer, prophylactic oophorectomy, death or last follow-up. The annual and cumulative incidence rates of ovarian cancer were estimated. Results: Over a mean follow-up period of 4.7 years (ranges 0–22.6), 195 incident ovarian or fallopian tube cancers were diagnosed (169 [86%] ovarian cancers, 22 [11%] fallopian tube cancers and four [2%] cancers that involved both the ovaries and fallopian tubes). Of these, 45 (23%) cancers were diagnosed at preventive surgery (occult cancers). The cumulative risk of ovarian cancer to age 80 was 49% for BRCA1 and 21% for BRCA2 mutation carriers. The mean age at diagnosis was 51.3 years (ranges 33–84) among women with a BRCA1 mutation and 61.4 years (ranges 44–80) among women with a BRCA2 mutation. Conclusion: Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects.

AB - Objectives: For women at high risk of developing ovarian cancer, it is important to provide an accurate recommendation for the optimal age for preventive surgery in order to maximize the preventative effect while delaying symptoms associated with early surgical menopause. The goal of the current study was to estimate age-specific incidence rates of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Methods: From our international registry, we identified 5689 women with no previous diagnosis of ovarian or fallopian tube cancer or preventive oophorectomy. Women were followed from the date of completion of the baseline questionnaire until either a diagnosis of ovarian or fallopian tube cancer, prophylactic oophorectomy, death or last follow-up. The annual and cumulative incidence rates of ovarian cancer were estimated. Results: Over a mean follow-up period of 4.7 years (ranges 0–22.6), 195 incident ovarian or fallopian tube cancers were diagnosed (169 [86%] ovarian cancers, 22 [11%] fallopian tube cancers and four [2%] cancers that involved both the ovaries and fallopian tubes). Of these, 45 (23%) cancers were diagnosed at preventive surgery (occult cancers). The cumulative risk of ovarian cancer to age 80 was 49% for BRCA1 and 21% for BRCA2 mutation carriers. The mean age at diagnosis was 51.3 years (ranges 33–84) among women with a BRCA1 mutation and 61.4 years (ranges 44–80) among women with a BRCA2 mutation. Conclusion: Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85048708377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048708377&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.05.011

DO - 10.1016/j.ygyno.2018.05.011

M3 - Article

VL - 150

SP - 85

EP - 91

JO - Gynecologic Oncology

T2 - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -